MMP9 and melanoma: Much like its analog ND322 we have previously used in a melanoma model of metastasis24 and therapy resistance25; and the prototypic SB-3CT,41(R)-ND336 is a slow-binding inhibitor of MT1-MMP and the gelatinases MMP2 and MMP9 (Figure 6A, inhibition constants—ki—and type of inhibition).